CELC
Price
$53.35Alerts
Change
-$2.96 (-5.26%)
Updated
Nov 20 closing price
Capitalization
3.27B
123 days until earnings call
Intraday BUY SELL Signals
PRAX
Price
$300.43Alerts
Change
-$10.47 (-3.37%)
Updated
Nov 20 closing price
Capitalization
7.75B
101 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CELC vs PRAX

CELC vs PRAX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CELC vs. PRAX commentary
Nov 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELC is a Hold and PRAX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CELC with price predictions
Nov 20, 2026

CELC's RSI Oscillator slumps into oversold zone

The RSI Indicator for CELC moved into overbought territory on November 20, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +9.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELC advanced for three days, in 249 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

CELC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CELC as a result. In 79 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for CELC turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 42 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for CELC entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CELC's P/B Ratio (-255.705) is very low in comparison to the industry average of (3.596). P/E Ratio (-15.533) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. CELC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for PRAX with price predictions
Nov 20, 2026

PRAX's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for PRAX turned positive on October 20, 2026. Looking at past instances where PRAX's MACD turned positive, the stock continued to rise in 41 of 43 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on PRAX as a result. In 82 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.

PRAX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PRAX crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +1.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRAX advanced for three days, in 258 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

The Aroon Indicator entered an Uptrend today. In 179 of 201 cases where PRAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.

Bearish Trend Analysis

The 10-day RSI Indicator for PRAX moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 29 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 55 of 63 cases where PRAX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.

The 50-day moving average for PRAX moved below the 200-day moving average on October 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

PRAX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.780) is normal, around the industry mean (3.596). P/E Ratio (-21.421) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. PRAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
CELC vs PRAX: Fundamental Ratings
CELC
PRAX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
1
Undervalued
19
Undervalued
PROFIT vs RISK RATING
1..100
69100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
8140
P/E GROWTH RATING
1..100
2136
SEASONALITY SCORE
1..100
3950

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CELC's Valuation (1) in the Miscellaneous Commercial Services industry is in the same range as PRAX (19) in the null industry. This means that CELC’s stock grew similarly to PRAX’s over the last 12 months.

CELC's Profit vs Risk Rating (69) in the Miscellaneous Commercial Services industry is in the same range as PRAX (100) in the null industry. This means that CELC’s stock grew similarly to PRAX’s over the last 12 months.

PRAX's SMR Rating (97) in the null industry is in the same range as CELC (100) in the Miscellaneous Commercial Services industry. This means that PRAX’s stock grew similarly to CELC’s over the last 12 months.

PRAX's Price Growth Rating (40) in the null industry is somewhat better than the same rating for CELC (81) in the Miscellaneous Commercial Services industry. This means that PRAX’s stock grew somewhat faster than CELC’s over the last 12 months.

CELC's P/E Growth Rating (21) in the Miscellaneous Commercial Services industry is in the same range as PRAX (36) in the null industry. This means that CELC’s stock grew similarly to PRAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELCPRAX
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
87%
Momentum
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
87%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 14 days ago
85%
Bullish Trend 4 days ago
85%
Declines
ODDS (%)
Bearish Trend 5 days ago
85%
Bearish Trend 6 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
Aroon
ODDS (%)
Bearish Trend 7 days ago
85%
Bullish Trend 3 days ago
89%
COMPARISON
Comparison
Nov 22, 2026
Stock price -- (CELC: $53.35 vs. PRAX: $300.43)
Brand notoriety: CELC and PRAX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELC: 55% vs. PRAX: 169%
Market capitalization -- CELC: $3.27B vs. PRAX: $7.75B
CELC [@Biotechnology] is valued at $3.27B. PRAX’s [@Biotechnology] market capitalization is $7.75B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELC’s FA Score shows that 2 FA rating(s) are green while PRAX’s FA Score has 1 green FA rating(s).

  • CELC’s FA Score: 2 green, 3 red.
  • PRAX’s FA Score: 1 green, 4 red.
According to our system of comparison, PRAX is a better buy in the long-term than CELC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELC’s TA Score shows that 4 TA indicator(s) are bullish while PRAX’s TA Score has 6 bullish TA indicator(s).

  • CELC’s TA Score: 4 bullish, 4 bearish.
  • PRAX’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, PRAX is a better buy in the short-term than CELC.

Price Growth

CELC (@Biotechnology) experienced а -17.12% price change this week, while PRAX (@Biotechnology) price change was -8.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.

Reported Earning Dates

CELC is expected to report earnings on Mar 25, 2027.

PRAX is expected to report earnings on Mar 03, 2027.

Industries' Descriptions

@Biotechnology (-11.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been closely correlated with IMA. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if CELC jumps, then IMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
-5.26%
IMA - CELC
76%
Closely correlated
-1.51%
SLXN - CELC
50%
Loosely correlated
-12.67%
COGT - CELC
48%
Loosely correlated
-3.70%
IMTX - CELC
45%
Loosely correlated
-3.03%
ABVX - CELC
43%
Loosely correlated
-9.24%
More

PRAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with IMVT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRAX
1D Price
Change %
PRAX100%
-3.37%
IMVT - PRAX
45%
Loosely correlated
-2.31%
FULC - PRAX
44%
Loosely correlated
-0.54%
IMMX - PRAX
44%
Loosely correlated
-1.14%
CGEM - PRAX
43%
Loosely correlated
-1.98%
CELC - PRAX
43%
Loosely correlated
-5.26%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MSMR34.08-0.16
-0.46%
McElhenny Sheffield Managed Risk ETF (MSMR)
HFRO4.99-0.15
-2.92%
Highland Opportunities and Income Fund
PBUS69.08-2.63
-3.67%
Invesco MSCI USA ETF (PBUS)
AMGR22.08-1.10
-4.76%
Amana Growth ETF (AMGR)
WDCX4.81-1.53
-24.13%
Tradr 2X Long WDC Daily ETF (WDCX)